Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma

Table 3 Treatment-emergent and drug-related adverse events

Adverse event			Participants, n (%)
	Grade I	Grade II	Grade III	Grade IV
Hematological
Decreased platelet count	14 (21.2)	8 (12.1)	3 (4.5)	0 (0)
Decreased neutrophil count	15 (22.7)	11 (16.7)	2 (3.0)	0 (0)
Non-hematological
Elevated alanine	30 (45.5)	8 (12.1)	4 (6.1)	4 (6.1)
Elevated serum bilirubin	20 (30.3)	26 (39.4)	5 (7.6)	0 (0)
Nausea and vomiting	32 (48.5)	8 (12.1)	0 (0)	0 (0)
Pain	29 (43.9)	11 (16.7)	0 (0)	0 (0)
Fever	4 (6.1)	2 (3.0)	0 (0)	0 (0)
Diarrhea	10 (15.2)	6 (9.1)	0 (0)	0 (0)
Hand-foot skin reaction	7 (10.6)	16 (24.2)	4 (6.1)	0 (0)
Neurotoxicity	18 (27.3)	7 (10.6)	0 (0)	0 (0)

Data are the number of patients, with percentages in parentheses; all participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma.